Navigation Links
Two-Thirds of Surveyed U.S. Neurologists Have Prescribed Genzyme's Aubagio to Their Multiple Sclerosis Patients at One Year Post-Launch
Date:11/25/2013

EXTON, Pa., Nov. 25, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that two-thirds of surveyed U.S. neurologists have prescribed Genzyme's Aubagio, the second oral disease-modifying therapy (DMT) to reach the multiple sclerosis (MS) market, to at least one of their MS patients at one year post-launch. This increase in prescriber base represents a modest expansion compared with six months ago when Biogen Idec's Tecfidera, the third oral DMT to market, became commercially available.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO )

Neurologist-reported patient share for Aubagio among relapsing-remitting MS (RR-MS) patients treated with DMTs has also remained stable at two percent over the past six months. Reflecting increased product awareness and neurologist familiarity compared with earlier in the launch, significantly more surveyed neurologists now know that Aubagio is dosed once daily, providing a potential point of differentiation with recently launched, twice-daily Tecfidera. In fact, while Aubagio's oral formulation continues to be identified top-of-mind as the product's single biggest advantage compared with other currently available treatment options for MS, more surveyed neurologists now mention Aubagio's once-daily administration as its biggest advantage than at one, three, and six months post-launch.  

The recently published LaunchTrends®: Aubagio Wave 4 report finds that, over the next six months, surveyed neurologists expect Aubagio's patient share among DMT-treated RR-MS patients to increase significantly to 6 percent. This patient share nearly matches that of Novartis's Gilenya (7 percent), the first-to-market
'/>"/>

SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. According to Surveyed Oncologists in the EU5, Zytiga Has Heavily Penetrated Second-Line Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and is Displacing Jevtana to Later-Line mCRPC
2. Surveyed U.S. and European Neurologists Agree that a Therapys Effect on Physical Disability is the Most Important Attribute Influencing Prescribing Decisions in Secondary-Progressive Multiple Sclerosis
3. Despite the Recent Availability of Xtandi, Zytiga Continues to Dominate the Second-Line Metastatic Castrate-Resistant Prostate Cancer Setting, According to Surveyed U.S. Oncologists and Urologists
4. Surveyed U.S. Physicians Indicate That Xarelto and Apixaban Will Benefit From the Lack of Use of a Fast-Acting Injectable Anticoagulant in the Treatment and Secondary Prophylaxis of Deep Vein Thrombosis/Pulmonary Embolism
5. Surveyed U.S. Neurologists Would Prescribe Biogen Idecs Tecfidera to 20 Percent of Their Patients with Relapsing-Remitting Multiple Sclerosis (RR-MS)
6. Surveyed U.S. Pulmonologists Expect to Treat Nearly 50 Percent of Their Severe, Refractory Asthma Patients With a Biologic or Biosimilar Version of Xolair By the End of 2018
7. For Treating Clostridium difficile Infections, Surveyed Infectious Disease Specialists Agree That Effect on Recurrence Rate is One of the Drug Attributes that Most Influences Their Prescribing Decisions
8. The Majority of Surveyed Gastroenterologists in the EU5 Identify Remicade as Their Most Preferred Biologic for the Treatment of Ulcerative Colitis
9. For Chronic Obstructive Pulmonary Disease, Surveyed Pulmonologists Indicate That Improved Effect on Quality of Life is One of the Greatest Unmet Needs
10. For Second- and Subsequent-Line Metastatic Castrate-Resistant Prostate Cancer, Surveyed Oncologists Indicate that Improved Symptom Control and Quality of Life is one of the Greatest Unmet Needs
11. Rising Drug Resistance is Driving Early-Line Use of Powerful Antibiotics Such as Carbapenems for Gram-Negative Infections, According to Surveyed EU5 Physicians
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... -- Market research firm Kalorama information says that 2014 will ... the medical device industry.  The firm thinks the $360 ... 3% growth this year, which led firms to look ... and entrance by acquisition into new competitive zones.  The ... The Global Market for Medical Devices, 5 th ...
(Date:11/21/2014)... , 21. November 2014 Michael ... sich am Morgen des 14. Februar 2014 zugetragen hat. ... wohl kaum vergessen. Video - http://youtu.be/5cVoMCe0uiE ... ich dabei war, mein morgendliches Training zu machen", erzählt ... zu der Zeit begeisterte Anhänger der CrossFit-Trainingsmethode. ...
(Date:11/21/2014)...  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ) ... public offering of $50,000,000 of shares of its common ... offering will consist of 49,751,244 shares of common stock ...  Lexicon has also granted the underwriters a 30-day option ... stock.  All of the shares in the offering will ...
Breaking Medicine Technology:Kalorama: 2014 The "Year of The Buy" in Medical Device Industry 2Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 2Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 3Lexicon Announces Pricing Of Common Stock Offering 2Lexicon Announces Pricing Of Common Stock Offering 3
... Japan, April 15, 2011 Takeda Pharmaceutical Company Limited ... today announced that EDARBI (azilsartan medoxomil), an angiotensin II ... or high blood pressure, is now available by prescription ... Drug Administration (FDA) approved EDARBI on February 25, 2011 ...
... 2011 Theramed Corporation ("Theramed") announces that it ... for the EBB® Complete Tamponade System and the ... devices used to advance the practice of obstetrics, ... medical device products have been approved for sale ...
Cached Medicine Technology:EDARBI (azilsartan medoxomil), Now Available in U.S. Pharmacies for Patients With Hypertension 2EDARBI (azilsartan medoxomil), Now Available in U.S. Pharmacies for Patients With Hypertension 3EDARBI (azilsartan medoxomil), Now Available in U.S. Pharmacies for Patients With Hypertension 4EDARBI (azilsartan medoxomil), Now Available in U.S. Pharmacies for Patients With Hypertension 5Theramed Secures Exclusive Canadian Distribution Rights for Two Novel Obstetrics Products from Glenveigh 2
(Date:11/23/2014)... AngelWeddingDress.com has recently updated its online store, offering ... “If you are looking for gorgeous beach wedding dresses ... Here you can enjoy 70% off discounts and all ... big marriage ceremony is the most important dream of ... is uppermost priority. Ophelia, one of customers, said, “I ...
(Date:11/23/2014)... Wright & Schulte LLC recently filed 40 C8 ... residents who allege that they developed thyroid disease, high ... C8 contaminated water released by the DuPont Washington ... C8 complaints, the plaintiffs were exposed to the C8 ... least one of the six water districts affected by ...
(Date:11/22/2014)... Cancer researchers in New York and Minnesota believe ... and the growth and spread of mesothelioma. Click ... Surviving Mesothelioma website. , Doctors at Memorial Sloan ... just released their study on tunneling nanotubes (TnTs), actin-based ... found that mesothelioma cells contain many more ...
(Date:11/22/2014)... BambooFlooringChina.com is a famous brand in the bamboo ... collection of bamboo mats ; the new models are ... , According to the sales manager of BambooFlooringChina.com, Bamboo ... highly renewable resource. Their bamboo mats are 100% made from ... from natural bamboo with caramel bamboo strips. , ...
(Date:11/22/2014)... 22, 2014 In order to provide better ... of cocktail party dresses. The business knows that a suitable ... occasions. , Now, the party dresses supplier’s high ... off. As the leading company in fashion industry, LunaDress understands ... for every customer. So it always raises the professional level ...
Breaking Medicine News(10 mins):Health News:Beach Wedding Dresses Added to Outstanding Online Dress Company AngelWeddingDress.com 2Health News:40 C8 Lawsuit Claims Filed By Wright & Schulte LLC Alleged Serious Illness Due To C8 Contaminated Water In Ohio And West Virginia 2Health News:40 C8 Lawsuit Claims Filed By Wright & Schulte LLC Alleged Serious Illness Due To C8 Contaminated Water In Ohio And West Virginia 3Health News:40 C8 Lawsuit Claims Filed By Wright & Schulte LLC Alleged Serious Illness Due To C8 Contaminated Water In Ohio And West Virginia 4Health News:Study Links Cellular ‘Tunnels’ to Mesothelioma Proliferation, According to Surviving Mesothelioma 2Health News:Trendy Bamboo Mats Online Now By BambooFlooringChina.com 2Health News:LunaDress Unveils Fabulous Cocktail Party Dresses 2
... of Oregon Health & Science University, received a research ... (NTI) to study a method that could more accurately ... ill or obese trauma patients. Schreiber,s study is ... NTI, a nonprofit organization dedicated to funding trauma research ...
... (ESMO), the leading professional organization for medical oncology ... been included among the medical specialties covered by ... as announced yesterday by the Commission. The decision ... between ESMO, key national societies and EU Member ...
... radiation inside a tumour using,boron-10 and thermal neutrons. Boron-10 ... a special carrier substance (phenylalanine), after which the tumour ... the boron to generate high-LET radiation, which may destroy ... may be sufficient to destroy a tumour, while keeping ...
... , FRIDAY, March 4 (HealthDay News) -- ... they have good parks and playgrounds in their neighborhoods, ... of 171 nine-year-old children to give their opinions about ... the amount of time their children spent watching television, ...
... (HealthDay News) -- An analysis of breast tissue may help ... new study reports. Researchers analyzed what they describe as ... that the way collagen fibers -- the main component of ... diagnosis and help determine treatment. Collagen not only surrounds ...
... (ASM) will hold its 111th General Meeting May ... meeting will feature approximately 3,000 individual scientific presentations ... expected attendance of 10,000. Microbiologists study living ... critical to human and animal health, agriculture, the ...
Cached Medicine News:Health News:BNCT, a new-generation radiation treatment, is effective in advanced head and neck cancer 2Health News:Tissue Analysis May Help Predict Breast Cancer Outcome 2Health News:American Society for Microbiology to host 111th General Meeting in New Orleans 2
... Pipette is a synonym for pipetting accuracy, ... design, and superior operating comfort. Its single, ... measuring stroke and blow-out as well as ... ensures utmost accuracy and precision. Ejection sleeve ...
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
... A fixed pipette is ideal ... single volume. Fixed volume FInnpipettes ... advantages as other Finnpipette Digital ... Super blow-out (1-40ul), Soft-touch tip ...
Medicine Products: